October 17th 2024
Oncology experts share notable clinical trials and up-and-coming therapies presented at the 2024 ESMO Congress.
October 2nd 2024
Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.
October 1st 2024
Targeted treatment as determined by mutational status was associated with ORR and PFS benefits in pretreated patients with metastatic solid tumors.
The addition of fecal microbiota transplantation to pembrolizumab and axitinib raised the efficacy of the combination in metastatic renal cell carcinoma.
September 25th 2024
Read about the early-phase sarcoma studies presented at the 2024 ESMO Congress that experts are keeping their eyes on.
Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.
September 24th 2024
Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.
September 19th 2024
The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.
Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.
September 18th 2024
Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.
Lenvatinib plus pembrolizumab led to tumor responses regardless of mismatch repair–proficient status, histology, and prior adjuvant therapy.
Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.
September 17th 2024
Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.
Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.
Neoadjuvant chemotherapy improved organ preservation in nasal and paranasal sinus squamous cell carcinoma.
September 16th 2024
Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.
Fianlimab plus cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma.
Durvalumab plus monalizumab and durvalumab plus ceralasertib showed promising long-term benefits in advanced NSCLC.
AI models like GigaPath may pave the way for other predictive models in cancer, as it deciphers diagnoses and mutations in a more granular method.
AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses and an acceptable safety profile across patients with MTAP-deleted solid tumors.